Drug intelligence / Profile preview

afatinib + tetracycline

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy approach where tetracycline antibiotics are used prophylactically or concurrently with afatinib to manage skin toxicities, particularly acneiform rash, associated with afatinib treatment in non-small cell lung cancer (NSCLC) patients. Afatinib is a second-generation, irreversible ErbB-family blocker that covalently binds to and blocks signaling from EGFR, HER2, ErbB3, and ErbB4, while tetracyclines are used to prevent or reduce the severity of skin reactions, which are common adverse effects of EGFR inhibitors.

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TRIB2ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on afatinib + tetracycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on afatinib + tetracycline.

Explore the full profile